Group 1 - The company completed a placement agreement on January 20, 2026, successfully placing a total of 2.1 million shares at a price of HKD 92.85 per share to at least six subscribers [1] - The 2.1 million shares represent approximately 0.70% of the existing issued H shares and about 0.53% of the total issued shares prior to the placement [1] - The total proceeds from the placement amount to approximately HKD 195 million, with a net amount of about HKD 190 million after deducting commissions and related costs, resulting in a net issue price of approximately HKD 90.54 per share [1] Group 2 - The net proceeds from the placement will be allocated as follows: approximately 60% or HKD 114 million for funding clinical trials of the core product Tinengotinib for cholangiocarcinoma (CCA) and other indications [2] - About 30% or HKD 57.04 million will be used for the development of other products, including TT-00973, TT-01488, and other molecules [2] - Approximately 10% or HKD 19.01 million will be allocated for working capital and general corporate purposes [2]
药捷安康-B(02617)完成配售合共210万股，净筹约1.9亿港元